Weight loss drugs: Scaling up
Weight loss drugs have pushed the obesity therapeutics market to an inflection point, reshaping not only patient behaviour, healthcare spending and investor expectations, but also potentially the global economic outlook, as lower obesity rates could promise higher productivity and reduced long term healthcare costs.
In this episode of the Barclays Brief, Patrick Coffey speaks with Emily Field, Head of US Biopharmaceuticals Equity Research, to break down the forces driving this shift.
They pinpoint the key accelerants: the arrival of oral versions, rapid uptake among consumers, shifting…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.